Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bristol-Myers Squibb |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00028301 |
This study will compare 2 treatments in the way they affect cholesterol levels and the amount of HIV in the blood.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Atazanavir Drug: Lopinavir/Ritonavir |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Safety Study |
Official Title: | ARandomizedOpen-labelStudyoftheAntiviralEfficacyand SafetyofAtazanavirVersusLopinavir/Ritonavir(LPV/RTV), EachinCombinationwithTwoNucleosidesinSubjectsWho HaveExperiencedVirologicFailurewithPriorProteaseInhibitor-ContainingHAARTRegimen(s) |
Ages Eligible for Study: | 16 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
Exclusion Criteria
Patients will not be eligible for this study if they:
Study ID Numbers: | 302D, AI424-043 |
Study First Received: | December 20, 2001 |
Last Updated: | October 1, 2007 |
ClinicalTrials.gov Identifier: | NCT00028301 |
Health Authority: | United States: Food and Drug Administration |
HIV Protease Inhibitors RNA, Viral Reverse Transcriptase Inhibitors Anti-HIV Agents Viral Load |
Lipids ABT 378 Antiretroviral Therapy, Highly Active Lipoproteins, LDL Cholesterol |
Virus Diseases Sexually Transmitted Diseases, Viral Lopinavir Ritonavir HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Atazanavir Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections HIV Protease Inhibitors Slow Virus Diseases Anti-HIV Agents Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections |